Molecular analysis of the MVK and TNFRSF1A genes in patients with a clinical presentation typical of the hyperimmunoglobulinemia D with periodic fever syndrome: a low-penetrance TNFRSF1A variant in a heterozygous MVK carrier possibly influences the phenotype of hyperimmunoglobulinemia D with periodic fever syndrome or vice versa.
OBJECTIVE
To describe biochemical findings and the spectrum of mevalonate kinase (MVK) gene mutations as well as an associated TNFRSF1A low-penetrance variant in a series of patients with clinical features of the hyperimmunoglobulinemia D with periodic fever syndrome (HIDS).


METHODS
The MVK gene was sequenced in 8 children and 1 adult (including 2 siblings) fulfilling the clinical criteria for HIDS. In addition, sequencing of exons 2, 3, 4, and 6 of the TNFRSF1A gene was performed in patients with only one or no MVK mutation. Mevalonate kinase (MK) enzyme activity in leukocytes and renal excretion of mevalonic acid were also measured.


RESULTS
Mutations in the coding region of the MVK gene were detected in 6 patients, and the most common mutation was V377I. Among these patients were 2 novel mutations, both of which were located in exon 6. These novel mutations resulted in the substitution of tryptophan (TGG) by a stop codon (TGA) at amino acid position 188 (W188X) and in the exchange of valine (GTG) for alanine (GCG) at amino acid position 203 (V203A). In 1 patient, a combination of one MVK (V377I) mutation and one TNFRSF1A (R92Q) mutation was present. The patient's clinical phenotype resembled a mixture of variant-type HIDS and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Her IgD values varied between normal and slightly increased, and the MK activity was in the low-normal range, while urinary mevalonate concentrations were always normal.


CONCLUSIONS
The genotype findings indicate that a relatively small number of genes may be involved in the clinical manifestation of HIDS, with low-penetrance TNFRSF1A variants possibly influencing the HIDS phenotype or MVK mutations contributing to TRAPS.
Stojanov
Silvia
S
Department of Infectious Diseases Immunology, Children's Hospital, University of Munich, Munich, Germany. Silvia.Stojanov@med.uni-muenchen.de
Lohse
Peter
P
Lohse
Pia
P
Hoffmann
Florian
F
Renner
Ellen D
ED
Zellerer
Stephanie
S
Kéry
Anja
A
Shin
Yoon S
YS
Haas
Dorothea
D
Hoffmann
Georg F
GF
Belohradsky
Bernd H
BH
D000293:Adolescent; D000328:Adult; D019943:Amino Acid Substitution; D015703:Antigens, CD / Q000235:genetics*; D002648:Child; D010505:Familial Mediterranean Fever / Q000235:genetics* / Q000378:metabolism; D005260:Female; D006579:Heterozygote; D006801:Humans; D006942:Hypergammaglobulinemia / Q000235:genetics* / Q000378:metabolism; D007072:Immunoglobulin D / Q000097:blood; D007668:Kidney / Q000378:metabolism; D008297:Male; D019683:Penetrance; D010641:Phenotype; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics* / Q000378:metabolism; D022821:RNA Splice Sites / Q000235:genetics; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics*; D047888:Receptors, Tumor Necrosis Factor, Type I
D015703:Antigens, CD; D007072:Immunoglobulin D; D022821:RNA Splice Sites; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D017853:Phosphotransferases (Alcohol Group Acceptor); C021796:mevalonate kinase